U.S. markets closed

Allena Pharmaceuticals, Inc. (ALNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.7753-0.0386 (-4.74%)
At close: 4:00PM EDT
0.7898 +0.01 (1.87%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close0.8139
Open0.8122
Bid0.7881 x 1100
Ask0.7898 x 1100
Day's Range0.7702 - 0.8190
52 Week Range0.7700 - 2.7800
Volume2,574,569
Avg. Volume1,670,846
Market Cap58.23M
Beta (5Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.9210
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Allena Pharma Stock Under Pressure After Equity Raise Of $28M
    Benzinga

    Allena Pharma Stock Under Pressure After Equity Raise Of $28M

    Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 million, the offering will close by July 16. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants have an exercise price of $1.25 per share, are exercisable immediately, and have a term of five years. The Company intends to use the proceeds for working capital

  • Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    GlobeNewswire

    Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Company’s common stock

  • Allena Pharmaceuticals Provides Update on Clinical Development Programs
    GlobeNewswire

    Allena Pharmaceuticals Provides Update on Clinical Development Programs

    -ALLN-346 successfully completes Phase 1b safety study; on track to start two Phase 2a studies in Q3 2021 with initial data expected in Q4 2021- -Reloxaliase advancing in URIROX-2 Pivotal Phase 3 study; revised interim analysis now targeted for Q1 2022- NEWTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral enzyme therapeutics to treat patien